Results 41 to 50 of about 14,204,460 (231)

Nail Toxicities Associated With Anticancer Therapies in Children

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Nail toxicities are a frequent yet often underrecognized component of dermatologic adverse events in children receiving anticancer therapies. Both conventional cytotoxic chemotherapy and newer targeted agents can affect the nail matrix, nail bed and periungual tissues, producing a broad spectrum of clinical manifestations that range from ...
Luca Rapparini, Michela Starace
wiley   +1 more source

Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders

open access: yes, 2008
Langerin is a type II transmembrane C-type lectin associated with the formation of Birbeck granules in Langerhans cells. Langerin is a highly selective marker for Langerhans cells and the lesional cells of Langerhans cell histiocytosis. Although Langerin
Chu, Peiguo G.   +2 more
core   +1 more source

Histiocytosis: a review focusing on neuroimaging findings

open access: yesArquivos de Neuro-Psiquiatria, 2014
Objective: Histiocytosis is a systemic disease that usually affects the central nervous system. The aim of this study is to discuss the neuroimaging characteristics of Langerhans cell histiocytosis (LCH), the most common of these diseases; and the non ...
Larissa Barcessat Gabbay   +4 more
doaj   +1 more source

Unravelling a hidden case of Erdheim-Chester disease in persistent pericardial effusion

open access: yesRomanian Journal of Cardiology
Erdheim-Chester disease (ECD) is a rare non-Langerhans cell, non-familial multisystemic histiocytosis, with widespread manifestations and of highly variable severity.
Alexandru Trenchea   +6 more
doaj   +1 more source

Juvenile xanthogranuloma of the cerebellopontine angle: A case report and review of the literature

open access: yesOtolaryngology Case Reports, 2019
Juvenile xanthogranuloma (JXG) is a non-Langerhans cell histiocytosis, most often presenting with skin lesions of the head, neck, and upper trunk. Intracranial presentations have been previously described, however, due to its rarity, treatment algorithms
Sarah M. Tittman   +6 more
doaj   +1 more source

Cutaneous Rosai‐Dorfman Disease With MAP2K1 Mutation Treated With Encorafenib and Binimetinib

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Rosai‐Dorfman disease (RDD) is a rare histiocytic disorder with unifocal to multisystemic involvement. Activating mutations in the MAPK/ERK pathway can occur in up to 50% of RDD cases. We report a case of cutaneous RDD (C‐RDD) with facial and truncal lesions harboring an activating MAP2K1 (MEK1) mutation that showed a complete response to a ...
Melike Ak   +2 more
wiley   +1 more source

Solving a Mystery . . . 8 Years Later

open access: yesJournal of Investigative Medicine High Impact Case Reports, 2018
Erdheim-Chester disease is a rare non-Langerhans cell histiocytosis with multisystem involvement and insidious symptoms. In this article, we describe an interesting case of Erdheim-Chester disease that was eventually diagnosed 8 years after symptoms ...
Hayan Jouni MD   +2 more
doaj   +1 more source

Multicentric reticulohistiocytosis: a case report

open access: yesBMC Research Notes, 2018
Background Multicentric reticulohistiocytosis is a rare form of non-langerhans cell histiocytosis presenting with skin changes and erosive arthritis. Infiltration of histiocytes and multinucleated giant cells are typical histological findings and confirm
Azadèh Farokhi   +3 more
doaj   +1 more source

Eosinophilic Granuloma: A Rare and Often Benign Condition Presenting as a Lump on the Head, which was Easily Treated

open access: yesEuropean Journal of Case Reports in Internal Medicine, 2021
Eosinophilic granuloma is a localized, non-invasive form of Langerhans cell histiocytosis. It usually develops in the long bones and is more frequent in children under the age of 10 years. It is very rare in adults.
Tatiana Pires   +5 more
doaj   +1 more source

MEK Inhibition with Trametinib in Patients with Non-Langerhans Cell Histiocytosis

open access: yesBlood, 2019
Background: Activation of the MAPK pathway through BRAF mutations or other molecular alterations is a hallmark of the non-Lagerhans cell histiocytosis (non-LCH) such Erdheim-Chester disease (ECD) or Rosai-Dorfman disease (RDD). Conventional clinical molecular testing of tumor tissue fails to identify targetable molecular alteration in about one third ...
Filip Janku   +5 more
openaire   +1 more source

Home - About - Disclaimer - Privacy